Biotech Values

[DewDiligence]

I think MRK is getting SGP at a good price, but there’s a hitch: SGP will lose its ex-US rights to Remicade if JNJ successfully challenges the MRK-SGP deal’s structure being a reverse merger in which SGP is the surviving legal entity. JNJ can argue that the reverse merger constitutes a kind of fraudulent conveyance to circumvent the Remicade change of control agreement.